Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 09, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in Ordinary Share ADRs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Material changes reported relate to the increase in share interests for specific individuals under the GlaxoSmithKline Executive Supplemental Savings Plan. These increases resulted from the re-investment of dividends paid on January 05, 2006, at a price of $51.95 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding internal share plan transactions.
Important Facts for Investors
- Transaction Type: Increase in Ordinary Share ADR interests via the Annual Investment Plan feature.
- Dividend Re-investment Price: $51.95 per share.
- Dividend Payment Date: January 05, 2006.
- Notified Individuals and Share Increases:
- Mr W Calhoun: 271.944 shares
- Dr J P Garnier: 263.833 shares
- Mr D Stout: 216.461 shares
- Dr T Yamada: 169.762 shares
- Mr J Ziegler: 69.733 shares
- Regulatory Basis: Notification made in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).